Oxidative stress, alpha-tocopherol therapy, and atherosclerosis
Tóm tắt
Atherosclerosis is the leading cause of morbidity and mortality in the United States. Evidence suggests that antioxidants, especially α-tocopherol (AT), have potential benefits with respect to cardiovascular disease. AT has been shown to decrease lipid peroxidation, to inhibit platelet adhesion, aggregation, and smooth muscle cell proliferation, to exert anti-inflammatory effects on monocytes, and to improve endothelial function. Low levels of AT are related to a higher incidence of cardiovascular disease and increased intakes appear to afford protection against cardiovascular disease. Although clinical trials with AT supplementation to date have been conflicting, the majority of evidence supports a benefit for AT supplementation in patients with pre-existing cardiovascular disease. Clearly, more clinical trials are required in individuals with increased oxidative stress before a definitive recommendation can be made with respect to AT supplementation in atherosclerosis.
Tài liệu tham khảo
Witztum JL, Steinberg D: Role of oxidized LDL in atherogenesis. J Clin Invest 1991, 88:1785–1792.
Berliner JA, Heinecke J: The role of oxidized lipoproteins in atherogenesis. Free Rad Biol Med 1996, 20:707–727.
Berliner JA, Navab M, Fogelman AM, et al.: Atherosclerosis: basic mechanisms, oxidation, inflammation and genetics. Circulation 1995, 91:2488–2496.
Steinberg D: Oxidative modification of LDL and atherogenesis. Circulation 1997, 95:1062–1071.
Devaraj S, Jialal I: Antioxidants and vitamins to reduce cardiovascular disease. Curr Atheroscler Rep 2000, 2:342–351.
Kaul N, Devaraj S, Jialal I: Alpha tocopherol and atherosclerosis. Exp Biol Med 2001, 226:5–12.
Jialal I, Devaraj S, Kaul N: The effect of alpha tocopherol on monocyte pro-atherogenic activity. Symposium: Molecular Mechanisms of Protective Effects of Vitamin E in Atherosclerosis. J Nutr 2001, 131:389S-394S.
Devaraj S, Jialal I: The effects of alpha-tocopherol on critical cells in atherogenesis. Curr Opin Lipidol 1998, 9:11–15.
Brown MS, Goldstein J: Lipoprotein metabolism in the macrophage. Ann Rev Biochem 1983, 52:223–261.
Thomas CE, Jackson RL, Ohlweiler DF, et al.: Multiple lipid oxidation products in LDL induce IL-1b release from human blood mononuclear cells. J Lipid Res 1994, 35:417–427.
Clinton S, Libby P: Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 1992, 116:1292–1300.
Salonen JT, Herttuala S, Yamamoto R, et al.: Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992, 339:883–887.
Regnstrom J, Nilsson J, Tornvall P, et al.: Susceptibility to LDL oxidation and coronary atherosclerosis in man. Lancet 1992, 339:1183–1186.
Carew TE, Schwenke DC, Steinberg D: Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect. Proc Natl Acad Sci U S A 1987, 84:7725–7729.
Morel DW, Chisolm GM: Antioxidant treatment of diabetic rats inhibits LDL oxidation and cytoxicity. J Lipid Res 1989, 30:1827–1831.
Bjorkhem I, Freyschuss HA, Breuer O, et al.: The antioxidant BHT protects against atherosclerosis. Arterioscler Thromb 1991, 11:15–20.
Sparrow CP, Doebber TW, Olszewski J, et al.: LDL is protected from oxidation and progression of atherosclerosis is slowed in cholesterol-fed rabbits by DPPD. J Clin Invest 1992, 89:1885–1891.
Walldius G, Erikson U, Olsson AG, et al.: The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994, 74:875–883.
Roberts L II, Morrow J: The generation and actions of isoprostanes. Biochim Biophys Acta 1997, 1345:121–135.
Patrano C, FitzGerald G: Isoprostanes—potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997, 17:2309–2315.
Pratico D, Luliano L, Mauriello A, et al.: Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997, 100:915–924.
Gniwotta C, Morrow J, Roberts L, et al.: Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1997, 17:3236–3241.
Jialal I, Grundy SM: The effect of dietary supplementation with alpha-tocopherol on the oxidative modification of LDL. J Lipid Res 1992, 33:899–906.
Devaraj S, Huet BA, Fuller CJ, et al.: Dose response comparison of RRR-AT and all-rac-AT on LDL oxidation. Arterioscler Thromb Vasc Biol 1997, 17:2273–2784.
Devaraj S, Hirany SV, Burk RF, et al.: Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin Chem 2001, 47:1974–1979.
Davi G, Ciabattoni G, Consoli A, et al.: In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999, 99:224–229.
Islam K, O’Byrne D, Devaraj S, et al.: Alpha-tocopherol supplementation decreases oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 2000, 150:217–224.
Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115–126.
Libby P: Molecular basis of the acute coronary syndromes. Circulation 1995, 91:2844–2850.
Hennig B, Toborek M, Barve S, et al.: Linoleic acid activates NFkb and induces NFkb-dependent transcription in cultured endothelial cells. Am J Clin Nutr 1996, 322–328.
Clinton S, Libby P: Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 1992, 116:1292–1300.
Raines E, Ross R: Multiple growth factors are associated with lesions of atherosclerosis: specificity or redundancy? Bioessays 1996, 18:271–282.
Hwang S, Ballantyne C, Sharrett R, et al.: Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in Carotid Atherosclerosis and Incident Coronary Heart Disease Cases (ARIC). Circualtion 1997, 96:4219–4225.
Caterina R, Basta G, Lazzerine G, et al.: Soluble VCAM-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17:2646–2654.
Rohde L, Lee R, Jamocochian M, et al.: Circulating cell adhesion molecules are correlated with ultrasound based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998, 18:1765–1770.
Ridker PH, Roitman J: Plasma concentration of soluble ICAM-1-1 and risks of future MI in apparently healthy men. Lancet 1998, 351:88–92.
Faruqui R, De La Motte C, diCorleto P: Alpha-tocopherol inhibits agonist-induced monocyte cell adherence to cultured human endothelial cells. J Clin Invest 1994, 94:592–600.
Cominacini L, Garbin U, Pasini AF, et al.: Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL, on human umbilical vein endothelial cells. Free Radic biol Med 1997, 22:117–127.
Martin A, Foxall T, Blumberg JB, et al.: AT inhibits LDL-induced adhesion of monocytes to human aortic endothelial cells in vitro. Arterioscler Thromb Vasc Biol 1997, 17:429–436.
Keaney JF Jr, Guo Y, Cunningham D, et al.: Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C Sstimulation. J Clin Invest 1996, 98:386–394.
Heitzer T, Yia Herttualla S, Wild E, et al.: Effect of vitamin E on endothelial vasodilator function in patients with hypercohlesteremia, chornic smoking, or both. J Am Coll Cardiol 1999, 33:499–505.
Libby P, Hanson G: Biology of disease: involvement of the immune system in atherogenesis: current knowledge and unanswered questions. Lab Invest 1991, 64:5–13.
Rus H, Niculescu Z, Vlaicu R: TNF-alpha in human arterial wall with atherosclerosis. Atherosclerosis 1991, 89:247–254.
Mantovani A, Sozzani S, Introna M: Endothelial activation by cytokines. Ann N Y Acad Sci 1997, 832:93–116.
Devaraj S, Li D, Jialal I: The effect of alpha-tocopherol supplementation on monocyte function: Decreased lipid oxidation, interleukin-1beta secretion, and monocyte adhesion to endothelium. J Clin Invest 1996, 98:756–763.
Devaraj S, Jialal I: Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type II diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation. Circulation 2000, 102:191–196.
Boscoboinik D, Szewczyk A, Hensey C, et al.: Inhibition of cell proliferation by alpha tocopherol, role of PKC. J Biol Chem 1991, 266:6188–6194.
Azzi A, Boscoboinik D, Marilley D, et al.: Vitamin E: a sensor and an information transducer of the cell oxidation state. Am J Clin Nutr 1995, 62(suppl):1337S-1364S.
Chatelain E, Boscoboinik D, Bartoli G, et al.: Inhibition of smooth muscle cell proliferation and protein kinase C activity by tocopherols and tocotrienols. Biochim Biophys Acta 1993, 1176:83–89.
Ozer N, Boscoboinik D, Azzi A: New roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis. Biochem Mol Biol Intl 1995, 35:117–124.
Tasinato A, Boscoboinik D, Bartoli G, et al.: d-a-tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties. Proc Natl Acad Sci U S A 1995, 92:12190–12194.
DeMaio S, King I SB, Lemo N, et al.: Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (TCA). J Am Coll Nutr 1992, 11:68–73.
LaFont A, Chai Y, Cornhill J, et al.: Effect of alpha-tocopherol on restenosis after angioplasty in a model of experimental atherosclerosis. J Clin Invest 1995, 95:1018–1025.
Steiner M: Influence of vitamin E on platelet function in humans. J Am Coll Nutr 1991, 10:466.
Davi G, Romano M, Mezzetti A, et al.: Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998, 97:953–957.
Steiner M: Effect of alpha tocopherol administration on platelet function in man. Thromb Haemostasis 1983, 49:73–77.
Takamatsu S, Takamatsu M, Satoh K: Effects on health of dietary supplementation with 100-mg d-alpha-tocopheryl acetate, daily for 6 years. J Intern Med Res 1995, 23:342–357.
Calzada C, Bruckdorfer K, Rice Evans C: The influence of antioxidant nutrients on platelet function in healthy volunteers. Atherosclerosis 1997, 128:97–105.
Freedman J, Farhat J, Loscalzo J, et al.: Alpha-tocopherol Inhibits aggregation of Human Platelets by a Protein Kinase C-Dependent Mechanism. Circulation 1996, 94:2434–2440.
Mabile L, Bruckdorfer K, Rice Evans C: Moderate supplementation with natural alpha tocopherol decreases platelet aggregation and low density lipoprotein oxidation. Atherosclerosis 1999, 147:177–185.
Stampfer M, Manson J, Colditz G, et al.: A prospective study of vitamin E supplementation and risk of coronary disease in women. N Engl J Med 1993, 328:1444–1449.
Rimm E, Stampfer M, Ascherio A, et al.: Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993, 328:1450–1456.
Losonczy K: Vitamin E and vitamin C supplement use and risk of all cause and coronary heart disease mortality in older persons: the established populations for epedemiologic studies of the elderly. Am J Clin Nutr 1996, 64:190–196.
Kushi L, Folsom A, Princas R, et al.: Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996, 334:1156–1162.
Knekt P, Reunanen A, Jarvinen R, et al.: Antioxidant vitamin intake and coronary mortality in a longitudnal population study. Am J Epidemiol 1994, 139:1180–1189.
Meyer F, Bairati I, Dagenais G: Lower ischemic heart disease (IHD) incidence and mortality among vitamin supplement users in a cohort of 2,226 men. 2nd International Conference. Antioxidant Vitamins and Beta-Carotene in Disease Prevention. Berlin: 1994.
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group: The effect of vitamin E and beta- carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330:1029–1035.
Virtamo J, Rapola JM, Ripatti S, et al.: Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med 1998, 158:668–675.
Rapola JM, Virtamo J, Ripatti S, et al.: Randomized trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997, 349:1715–1720.
Rapola JM, Virtamo J, Haukka JK, et al.: Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial [see comments]. JAMA 1996, 275:693–698.
Stephens NG, Parsons A, Schofeld P, et al.: Randomized controlled trial of vitamin E in patients with coronary artery disease. CHAOS. Lancet 1996, 347:781–786.
Jialal I, Fuller CJ, Huet BA: The effect of alpha tocopheol supplementation on LDL oxidation: a dose response study. Arterioscler Thromb 1995, 15:190–198.
GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447–455.
Jialal I, Devaraj S, Huet BA, et al.: GISSI-Prevenzione trial. Lancet 1999, 354:1554.
Yusuf S, Dagenais G, Pogue J, et al.: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:154–160.
Jialal I, Devaraj S: HOPE Study. N Engl J Med 2000, 342:154–160.
Kaul N, Devaraj S, Grundy S, et al.: Failure to demonstrate a major anti-inflammatory effect with alpha tocopherol supplementation (400 IU/day). Am J Cardiol 2001, 87:1320–1323.
Boaz M, Smetana S, Weinstein T, et al.: Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomized placebo controlled trial. Lancet 2000, 356:1213–1218.
Salonen JT, Nyyssönen K, Salonen R, et al.: Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000, 248:377–386.
Collaborative Group of the Primary Prevention Project (PPP): Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001, 357:89–95.
Brown BG, Zhou XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.